Official Title
Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Randomized, Parallel Group, Double-blind Placebo-controlled Clinical Trial
Brief Summary

Single-center study with a parallel group scheme, double-blind, randomized, placebo-controlled, to evaluate whether the addition to the investigator's hospital standard therapy of two vials of Bioarginina® per day in subjects with SARS-CoV-2 is useful for treatment of this pathology.

Detailed Description

Preliminary experiences conducted in patients affected by SARS-CoV-2 infection by adding the
daily oral administration of two vials of Bioarginina® to the standard therapy have shown
favorable effects on discharge times, on the recovery of the number of lymphocytes and on the
P \ F ratio between arterial pO2 and FiO2 breathed. In particular, for the latter parameter
there is almost a doubling of the recovery speed.

The investigators therefore, decided to undertake the present spontaneous, single-center
study with a parallel group scheme, double-blind randomized, placebo-controlled to evaluate
whether the addition to the standard therapy of two vials per day of Bioarginina® in subjects
of our hospital suffering from SARS-CoV-2 is useful for the treatment of this pathology.

Unknown status
COVID19

Dietary Supplement: Bioarginina®

Food supplement based on 1,66 grams of L-arginine

Eligibility Criteria

Inclusion Criteria:

- age> 18 years

- Diagnosis of COVID 19, confirmed by RT-PCR on a nasopharyngeal swab

- COVID 19 pneumonia with the following clinical characteristics: SpO2 in ambient air
<93% and Alveolar pressure of oxygen / inspiratory fraction of oxygen (PaO2 / FiO2 - P
/ F <300 mmHg.

- Lymphocytopenia defined as lymphocytes <1500 / mcL or <20% of white blood cells

Exclusion Criteria:

- History of intolerance to L-arginine

- Severe chronic pulmonary disease

- Pregnancy or breastfeeding

- Neutropenia due to neoplasms of the haematopoietic system or other organs with
invasion of the bone marrow

- Use of immunosuppressive drugs or cytotoxic chemotherapies within the previous three
weeks

- Refusal to give consent to participate in the study

Eligibility Gender
All
Eligibility Age
Minimum: 19 Years ~ Maximum: N/A
Countries
Italy
Locations

Azienda Ospedaliera Specialistica Dei Colli
Napoli, Italy

Investigator: barbara maglione
Contact: 3343293357
bmaglione@hotmail.com

Contacts

barbara maglione
3343293357 - 3343293357
bmaglione@hotmail.com

Giuseppe Fiorentino, Principal Investigator
Università degli Studi della Campania Luigi Vanvitelli

University of Campania "Luigi Vanvitelli"
NCT Number
MeSH Terms
COVID-19